Zhengxiong T. Li
Xuzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
Cost‑effectiveness of first‑line immunotherapy-based combination regimens for advanced renal cell carcinoma in China and the United States.
Journal: Human vaccines & immunotherapeutics
Published: August 22, 2026
Cost-effectiveness analysis of disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing advanced urothelial cancer.
Journal: Human vaccines & immunotherapeutics
Published: August 18, 2026
First-line sugemalimab plus chemotherapy for metastatic non-small-cell lung cancer: an updated cost-effectiveness analysis based on 4-year survival data.
Journal: Expert review of pharmacoeconomics & outcomes research
Published: August 15, 2026
Cost-effectiveness of fuzuloparib, with or without apatinib, for BRCA mutation HER2-negative metastatic breast cancer in China.
Journal: Frontiers in pharmacology
Published: April 24, 2026
Cost-effectiveness of sugemalimab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced oesophageal squamous cell carcinoma in China.
Journal: BMJ open
Published: February 24, 2026
Exploring the optimal regimen in advanced hepatocellular carcinoma: a protocol of individual patient data network meta-analysis of randomized controlled trials.
Journal: Frontiers in immunology
Published: February 05, 2026
Cost-effectiveness of sugemalimab plus chemotherapy as first-line therapy in advanced gastric cancer and gastroesophageal junction cancer.
Journal: Annals of medicine
Published: December 10, 2025
Cost-effectiveness analysis of anlotinib plus penpulimab versus sorafenib in the treatment of unresectable hepatocellular carcinoma.
Journal: Human vaccines & immunotherapeutics
Published: December 01, 2025
Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma: A cost-effectiveness analysis.
Journal: Cancer
Published: September 29, 2025
Cost-effectiveness of lurbinectedin with atezolizumab for extensive-stage small-cell lung cancer in the United States: impact of drug wastage reduction on economic outcomes.
Journal: BMC health services research
Published: September 15, 2025
Toripalimab plus chemotherapy as first-line treatment in extensive-stage small cell lung cancer: a health economic evaluation in China.
Journal: Frontiers in public health
Published: September 12, 2025
Cost-effectiveness analysis of toripalimab plus bevacizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China.
Journal: Frontiers in immunology
Published: July 30, 2025
Last Updated: 09/26/2026